A tool to predict risks in early stage lung cancers
Official title: CHIRP Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung Cancers
Funded at Emory University · NIH-10541900 · Data updated 2026-11-12
This study is testing a new computer tool called CHiRP that helps doctors figure out which patients with early-stage non-small cell lung cancer might not need extra chemotherapy after surgery, so they can avoid unnecessary treatment and side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | January 1, 2018 |
| Project end | December 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $552,153 |
| NIH project number | 5R01CA216579-07 |
| Project ID | NIH-10541900 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with early stage non-small cell lung cancer (stage I and II).
✕Less likely to help
Patients with advanced stage lung cancer or those who do not have non-small cell lung cancer may not benefit from this research.
What this research studies
This research focuses on developing a computerized tool called CHiRP that helps identify which patients with early stage non-small cell lung cancer (NSCLC) are at low risk for disease recurrence. By analyzing histologic data, the tool aims to determine whether patients will benefit from additional chemotherapy after surgery. This could prevent unnecessary treatment and its associated side effects for patients who are unlikely to gain any benefit. The approach combines advanced algorithms and biological assays to improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could help patients avoid unnecessary chemotherapy, reducing side effects and healthcare costs.
How similar studies have gone: Previous research has shown promise in using predictive tools for cancer treatment, but this specific approach with CHiRP is novel.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Madabhushi, Anant — Emory University
- Study coordinator: Madabhushi, Anant
Related research
Other NIH-funded projects on the same topics.
-
TRIM28 Inhibition for NOTCH2-Mutant Small Cell Lung Cancer
A new approach aims to exploit a weakness in a subset of small cell lung cancer by turning on immune-related signals when NOTCH2 is lost, potentially making tumors more visible to the immune system.
-
Genomic factors shaping lung cancer risk in Native Hawaiians and Pacific Islanders
This NIH grant focuses on understanding why Native Hawaiians, Pacific Islanders, and African Americans have higher lung cancer risk and poorer outcomes by studying tumor DNA and related molecular patterns.
-
PD-L1 PET tracer to guide immune therapy in non-small cell lung cancer
A Johns Hopkins team is testing a Gallium-68 PET tracer to better guide immune checkpoint therapy for people with non-small cell lung cancer.
-
Targeting SMARCA2 to treat lung cancers that lack SMARCA4
This work looks at whether blocking a protein called SMARCA2 can slow or stop lung cancers that have lost the related gene SMARCA4.
-
New medicines for lung cancers caused by KRAS or BRAF changes
Testing new medicines that block ERK/RAF signaling in people with lung cancer driven by KRAS or BRAF mutations.
-
Understanding lung cancer risks in Native Hawaiians
This research looks at the genetic differences in lung cancer among Native Hawaiians to better understand why they face higher risks and poorer outcomes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.